Tilray, Inc. (TLRY)
|Net Income (ttm)||-488.26M|
|Trading Day||January 26|
|Day's Range||18.00 - 19.85|
|52-Week Range||2.47 - 20.09|
Could there be more gains ahead for these recovering companies?
Aphria And Tilray: Option Strategy Enhances Returns And Mitigates Losses
It's good news all around for the marijuana marketers.
Tilray's products will treat patients with neuropathic pain, epilepsy and multiple sclerosis who aren't getting relief from existing treatments.
Tilray (TLRY) stock is heading higher on Tuesday after announcing a deal with France to supply it with medical marijuana. The post TLRY Stock Alert: 7 Things to Know Today About Tilray's Deal ...
Shares of Tilray Inc. surged 3.6% in premarket trading Tuesday, after the Canada-based cannabis company said it has been selected by France's National Agency for the Safety of Medicines and He...
Tilray® Selected by French National Agency to Supply GMP-Certified Medical Cannabis Products in France
NANAIMO, British Columbia & PARIS--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production, research, cultivation, and distribution, announced that it has been se...
Analysts point out: Oversupply and falling prices aren't good for profits.
Cannabis Watch: Cannabis stocks slide as investors lock in gains driven by hopes that Biden will usher in reforms
Cannabis stocks were mostly lower Monday as investors locked in some of the market's recent gains amid continued optimism for the sector following record sales in 2020 and as more states look ...
Let's look at four marijuana penny stocks that can deliver multi-fold returns once federal cannabis legalization occurs in the United States. The post 4 Marijuana Penny Stocks for a Blue-Led G...
The shares of several cannabis stocks are trading lower as cannabis names pullback following recent momentum.
Why this analyst thinks marijuana's market could be worth $40B
Vivien Azer, Cowen senior research analyst, joins 'The Exchange' to discuss her outlook for pot stocks and how the legislative approval timeline could affect marijuana-related stocks.
These hot stocks have already more than doubled -- and in one case more than tripled -- this month.
The moves felt like an investor retreat from recent price rises.
Nio, BlackBerry, Tilray, Five9 and Progyny were our top stock trades for Tuesday. Let's check out the charts after a long holiday weekend.
Could it have even more room to run?
Tilray: Momentum Could Carry The Stock Much Higher
Earnings, rising share prices, and a stock offering are all playing into the action.
Tilray (TLRY) stock is soaring higher on Friday after Cantor Fitzgerald increased its price target for merger partner Aphria (APHA). The post TLRY Stock: Why Tilray Shares Are Smoking Today ap...
Marijuana stocks are set to be the rage on Wall Street in hopes of legalization in and around the United States, which calls for keeping an eye on the likes of Tilray (TLRY) and Square (SQ).
Aphria price target raised by Cantor to reflect merger with Tilray as analyst deems earnings disappointing
Cantor Fitzgerald raised its 12-month stock price target for Canadian cannabis company Aphria Inc. to C$26 from C$11.75 on Friday, to factor in its merger with Tilray Inc. even though it was u...
Earnings from Aphria are moving Tilray shares today.
Aphria Inc. posted net cannabis revenue of CA$67.9 million for the second quarter of 2021 — 99% higher than in the prior-year quarter.
Medical pot is now legal in Mexico.
Is (TLRY) Outperforming Other Medical Stocks This Year?
We have highlighted stocks worth a look from the five best trading areas of the current year. This includes NVIDIA (NVDA), JPMorgan Chase (JPM), Beazer Homes (BZH), Tesla (TSLA) and Tilray (TL...
Tilray is about to become the world's largest cannabis company by revenue. Should you consider an investment?
When is the right time to buy stock in the cannabis market? The time is now!
Tilray (KL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Marijuana is now widely legal, and the industry will soon be gobbling up market share from its illicit competition.
Investors think the new administration in the U.S. could bring an inflection point for the industry.
Cannabis stocks rallied anew on Thursday, with the Cannabis ETF on track for its biggest weekly gain since March of 2020, as hopes the Democrat's victory in the Georgia Senate run-off will spu...
Tilray rallied after Democrats gained ground in the U.S. Senate, following two Georgia runoff elections. So, is Tilray stock a buy now?
One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.
Investors in the cannabis sector are feeling pretty good today.
The shares of several cannabis stocks are trading higher Wednesday in anticipation of results from Georgia's runoff election. A democratic win would be seen as favorable for cannabis legalizat...
Predicting market moves proves difficult again, but cannabis investors have high hopes for the future.
The marijuana industry's growth could be about to accelerate.
Cannabis Watch: Cannabis stocks stage strong rally as prospect of Democratic Senate spurs reform hopes
Cannabis stocks staged a strong rally on Wednesday, with most Canadian and U.S. companies posting double-digit percentage gains, buoyed by hopes the Democrats may take the Senate and pursue a ...
Pot stocks rallied on Wednesday as Georgia's Senate runoff elections lifted investors' hopes for nationwide decriminalization. Democrats are set to win both races in Georgia and win a slim maj...
Cannabis stocks surged on Wednesday as Democrats won a key U.S. Senate race in Georgia and led in another, moving closer to a stunning sweep that would give them control of Congress and power ...
Cannabis stocks Tilray, Canopy Growth and ACB are up in double digits as the Georgia runoff elections appear to flip the U.S. Senate blue. The post Cannabis Stocks: Why TLRY, CGC and ACB Stock...
The final weeks of 2020 brought a host of market-shaking headlines. However, one major headline only received a brief moment of scrutiny before getting subsumed by news of federal stimulus an...
Cannabis stocks rallied in premarket trade Wednesday, on hopes the Democrats may take the Senate after Raphael Warnock won one of two Senate runoffs in Georgia early Wednesday, according to th...
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
A positive analyst note was the apparent spark that lit a broad sector rally.
2020 saw increases of 80% in Canada and expectations are for that to double next year. California will lead revenue growth rates as the state continues to ramp up the industry.
Start Up Cannabis Nation (Podcast Transcript)
Earlier this month, cannabis growers Aphria (NASDAQ:APHA) and Tilray (NASDAQ:TLRY) announced a merger to create the largest enterprise in the industry by revenue.
Cannabis growth to continue 'substantially' in 2021: Parallel Cannabis CEO
When new cannabis laws go into effect across the U.S. in 2021, the industry may see some big changes. CNBC's "Squawk on the Street" team discusses this with William Wrigley, CEO of Parallel Ca...
Tilray engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, pharmacies, governments, and hospitals; and for researchers for commercial purposes, as well as compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, Israel, Ireland, New Zealand, South Africa, Switzerland, the United States, and the United Kingdom. The company was incorporated in 2018 and is hea... [Read more...]
Drug Manufacturers-Specialty & Generic
|IPO Date |
Jul 19, 2018
|Stock Exchange |
|Ticker Symbol |
In 2019, Tilray's revenue was $166.98 million, an increase of 287.15% compared to the previous year's $43.13 million. Losses were -$321.17 million, 374.2% more than in 2018.
According to 15 analysts, the average rating for Tilray stock is "Hold." The 12-month stock price forecast is 10.31, which is a decrease of -45.82% from the latest price.